Cargando…

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup

Detalles Bibliográficos
Autores principales:	Garrido, Pilar, Chouaki, Nadia, Serke, Monika, Giraud, Philippe, Ricardi, Umberto, Vallejo, Carmen, Visseren-Grul, Carla, Soldatenkova, Victoria, Novello, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ESMO Open 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519800/ https://www.ncbi.nlm.nih.gov/pubmed/28761728 http://dx.doi.org/10.1136/esmoopen-2016-000141

Ejemplares similares

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2014)

Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021)

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
por: Paz-Ares, Luis G, et al.
Publicado: (2010)

Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001
por: Watanabe, Kana, et al.
Publicado: (2021)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)
por: ZINNER, RALPH, et al.
Publicado: (2015)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer
por: Tao, Youmao, et al.
Publicado: (2016)

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
por: Kim, Jung Sun, et al.
Publicado: (2017)

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
por: Belani, Chandra P, et al.
Publicado: (2014)

Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
por: Bijelic, Lana, et al.
Publicado: (2012)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer
por: Ishihara, Masashi, et al.
Publicado: (2017)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
por: Li, Xin, et al.
Publicado: (2014)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
por: Bukhari, Ali A., et al.
Publicado: (2013)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Duodenal perforation in a patient with non-small cell lung cancer receiving Pemetrexed-Cisplatin combination
por: Hakeam, HA, et al.
Publicado: (2011)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer
por: Liu, Ke-Jun, et al.
Publicado: (2015)

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer
por: Otsubo, Kohei, et al.
Publicado: (2017)

A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed
por: Natsume, Maika, et al.
Publicado: (2017)

CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells
por: Zamagni, Alice, et al.
Publicado: (2020)

Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol
por: Kreuter, Michael, et al.
Publicado: (2007)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
por: La Monica, Silvia, et al.
Publicado: (2019)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
por: Oien, Derek B., et al.
Publicado: (2018)

Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review
por: Tang, Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tl45ullga449jhfgtd9j193ifu